12,372 trials
Bacterial Pneumonia · Community-Acquired Infections
Primary: Number of Participants With Early Clinical Response — 313; 321; 49; 47 Participants
Pervasive Developmental Disorder
Primary: Number of Participants Improved as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2) — 11; 3 participants
Parkinson's Disease · Freezing of Gait
Primary: Number of Participants With Treatment Emergent Adverse Events — 3; 1; 1; 1 Participants
Hereditary Angioedema (HAE)
Primary: Time-Normalized Number of Attacks (NNA) for Participants During a Treatment Period — 1.611; 3.931 Number of attacks — p=<0.0001
Non-Small-Cell Lung Carcinoma
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging — 8.8; 4.9 Months — p=<0.00001
Cytomegalovirus (CMV)-Positive Recipients · Allogeneic, Hematopoietic Cell Transplant (HCT)
Primary: Percentage of Participants With Composite of All-Cause Mortality and Adjudicated Cytomegalovirus End Organ Disease (CMV EOD) Through 1 Year Post Transplant — 30.20…
Agitation · Anesthesia · Pediatrics
Primary: Number of Participants With Emergence Delirium — 1; 7; 13; 7 participants
Hodgkin Lymphoma
Primary: Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF) — NA; NA months — p=0.035
Epilepsy
Primary: Number of Participants That Were Seizure-free — 17; 12 Participants — p=0.1972
Infections, Streptococcal
Primary: Number of Subjects With Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) Post Booster Between the Synflorix-Synflorix and Prevenar-Prevenar Groups — 24; 7…
Plaque Psoriasis
Primary: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) — 25.3; 3.9 percentage of participants — p=<0.001
Infections, Meningococcal
Primary: Number of Subjects With Vaccine Response for Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (rSBA-MenA…
Schizophrenia
Primary: Change From Baseline in PANSS(Positive and Negative Syndrome Scale) Total Score at Week 8 — -30.59; -33.56; -33.71; -36.31 score on a scale — p=<0.05
Hemophilia A
Primary: Number of Participants With Any Positive Inhibitor Development — 0; 0; 0 Participants
Severe Hemophilia B
Primary: Number of Participants With Any Positive Inhibitor Development — 0; 0; 0 Participants